Please use this identifier to cite or link to this item:
|Title:||Development of a high-activity 225Ac/213Bi radionuclide generator for synthesis of clinical doses of 213Bi-labelled biomolecules|
|Authors:||BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MIRZADEH Saed; BOLL Rose; MURPHY Karen; MORGENSTERN Alfred|
|Citation:||Proceedings of the 8th Sympoisum on Targeted Alpha Therapy p. 39|
|Publisher:||Oak Ridge National Laboratory|
|Type:||Articles in periodicals and books|
|Abstract:||The potential of applying 213Bi in targeted alpha therapy (TAT) of cancer and infectious diseases has been demonstrated in a wide body of preclinical studies and in an increasing number of clinical trials. The short-lived alpha emitter (T1/2 = 45.6 min) is conveniently available in clinical settings from 225Ac/213Bi radionuclide generators. Clinical trials on leukemia, neuroendocrine tumors and gliomas have demonstrated the favourable safety profile of TAT with 213Bi as well as the need for preparation of therapeutic doses of up to 6 GBq 213Bi per patient. Consequently 225Ac/213Bi radionuclide generators loaded with several GBq of 225Ac/213Bi are required to minimize the number of radiolabeling procedures and injections per patient. The established 225Ac/213Bi radionuclide generator system is based on the use of the organic cation exchange resin AG MP-50 (Bio-Rad). Standard generators made of 0.3 ml of resin provide constant yield of 213Bi elution and low parent breakthrough when loaded with 225Ac activities up to 1.8 GBq. However, when loaded with higher activities increasing radiolytic degradation of the organic resin leads to deterioration of generator performance. Here we present the development of an optimized generator design that allows the reliable operation at activities of 225Ac/213Bi up to 3 GBq (81 mCi).|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.